The Global Varicella Zoster HHV-3 Infections Market is driven by increasing incidence of viral diseases
The Varicella Zoster HHV-3 Infections Market deals with vaccines and therapeutics used in the treatment and prevention of Varicella and Herpes Zoster infections. These viral infections are caused by the reactivation of the Varicella Zoster virus or the human herpes virus 3, which remains dormant in the nervous system after primary infection (chickenpox). The development of live attenuated vaccines such as Zostavax and Shingrix have significantly boosted the protection against Herpes Zoster and its complications in adults and elderlies.
The Global Varicella Zoster (HHV-3) Infections Market is estimated to be valued at USD 1.79 billion in 2024 and is expected to reach USD 2.52 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2031.
Key players operating in the Varicella Zoster HHV-3 Infections market are Cangene Corporation, Novartis, GC Biopharma Corp, Pascoe Pharmazeutische Praeparate GmbH, SK Chemical Co. Ltd. These players are focused on ramping up production capacity and conducting research for developing improved vaccines with high efficacy and long-lasting effect.
The demand for Varicella Zoster HHV-3 Infections Market and vaccines is growing significantly driven by increasing incidence of herpes zoster disease globally, especially among the geriatric population. According to WHO, 1 in 3 people are expected to develop herpes zoster during their lifetime. The economic burden of managing herpes zoster is also substantial.
Varicella Zoster HHV-3 Infections Market – https://www.coherentmi.com/ind....ustry-reports/varice
